SlideShare uma empresa Scribd logo
1 de 25
Medical & Scientific Affairs (M & SA) A critical piece in the puzzle of building organizational equity Dr Karthik Anantharaman Head of Medical Team Integrated Disease Management Pvt Ltd
Presentation outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Objective of M & SA function understood to be in line with the  Vision of the organization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Market Leadership Partner of choice Employer of choice Patient
Roles & Responsibilities of M & SA understood to be in-line with  Differentiated Strategic Intent of organization Customer Few Disease Management Many Product Therapeutic Areas Offering Doctor Patients IDM Scientific rigour for patented ‘first in class’ brands Establish both ‘Science’ & ‘Story’ of the brand Health Outcome Partner to physicians to improve patient outcomes Establish brand as a ‘SOLUTION’ & not a tablet Most Large Pharma  Companies in India “ Differentiated” Intent
M & SA responsibility: The fine balance Scientific & Research based communication – Non product related, Focus on Disease Management, Guideline Compliance (fair, balanced, non-promotional, build organizational equity thru scientific excellence)  Science based product related discussions / objection handling / query management
Vision & Mission Statements ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Alignment to the organizational strategy  Complete alignment for the flawless execution and implementation of the strategy in accordance with the business needs.
M & SA : The New Industry Model ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
D.  Future H S A Working Model ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],M & SA  activities  shall have 2 components:  Activities common to all  members of  M & SA  +  Activities specific to  BU specific  M & SA
M & SA Responsibilities on lines of  Pharmaceutical Organizational Priorities (1) Direct Business Development Priorities (Conventional) (2) Incremental Business Development Priorities ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Responsibilities of M & SA  Sales Marketing RTM KAM  M & SA Medical / MRL / Regulatory Corporate Business (1) Direct Business Development Priorities (Conventional)
Responsibilities of M & SA  Sales PV IDM  Office of Compliance M & SA Medical / MRL / Regulatory External Partnerships CSR (2) Incremental Business Development Priorities PCP / Patient Support Programs
Completing the picture: All Responsibilities of M & SA  Sales Marketing RTM KAM  PV IDM  Office of Compliance M & SA Medical / MRL / Regulatory External Partnerships  Corporate Business CSR CSA / Patient Support Counselors
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
Role of Team M & SA in Business Strategy Strategy building team BUD + Marketing  + NBM Head – M & SA  Output = BU Strategy Strategy roll-out team Medical Advisor Marketing Manager M & SA Manager M & SA Implementation Pre-implementation (if any) (blue) & Post-implementation (green) M & SA  Inputs / feedback Into BU Strategy (Attachment 1)
M & SA  : Feedback & Performance Management Customers of M & SA  Internal customers (Sales & Marketing) External customers (Doctors) *RBM feedback on respective  M & SA(monthly)  (Attachment 4) **Training feedback (Attachment 5) M & SA Mgr Consolidated monthly feedback to individual M & SA  Individual Coaching & Counseling Supervisor Doctor feedback (consolidated monthly): **CME quality feedback (Attachment 6) **Medical Query quality feedback (Attachment 7) M & SA  Manager Monthly Field trip report  (Attachment 8) Assessment of Business Enabling Capabilities Assessment of Technical &  Management capabilities Assessment of Technical capabilities *Reported on last working day of the month **incorporated in monthly report
PPG/KRA Alignment of Team M & SA  Head M & SA  Regional  M & SA  Mgr Regional  M & SA  Mgr M & SA M & SA Regional  M & SA  Mgr M & SA Medical Director S & M Director  (consolidated for all BUs) BU specific (Aligned to BUD’s PPG) BU specific (Aligned to BUD’s PPG) BU specific (Aligned to BUD’s PPG)
Resource Planning - Methodology Variables Weightage CoP Network (Region-wise) (Focus segment for KOL Management) 50% Field Deployment 50% Number of medico-marketing activities based on BU strategy
 
Back-up Slides
Scope for future M & SA Job enrichment  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Mais conteúdo relacionado

Mais procurados

Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryMedical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
 
Optimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report SummaryOptimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report SummaryBest Practices
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan DrugsANCY JOSE
 
Medical Affairs Consortium
Medical Affairs Consortium Medical Affairs Consortium
Medical Affairs Consortium Best Practices
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“Arindam Pande
 
Key Opinion Leader Management
Key Opinion Leader ManagementKey Opinion Leader Management
Key Opinion Leader ManagementJames Wiliam
 
Medical Science Liaison (MSL) and KOL Regulatory Compliance
Medical Science Liaison (MSL) and KOL Regulatory ComplianceMedical Science Liaison (MSL) and KOL Regulatory Compliance
Medical Science Liaison (MSL) and KOL Regulatory ComplianceMedical Science Liaison Society
 
Strategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devicesStrategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devicesAnjan Banerjee
 
Key Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
Key Opinion Leader Compensation and KOL and Medical Science Liaison InteractionsKey Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
Key Opinion Leader Compensation and KOL and Medical Science Liaison InteractionsMedical Science Liaison Society
 
Medical Writing Canada
Medical Writing CanadaMedical Writing Canada
Medical Writing CanadaAmanda Strong
 
Early Phase Oncology Trials: A Study in Adaptation
Early Phase Oncology Trials: A Study in AdaptationEarly Phase Oncology Trials: A Study in Adaptation
Early Phase Oncology Trials: A Study in AdaptationPAREXEL International
 
Compensation in clinical trial
Compensation in clinical trialCompensation in clinical trial
Compensation in clinical trialBhaumik Bavishi
 
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Manny Garcia MD
 
Best in-class Medical Science Liasons
Best in-class Medical Science LiasonsBest in-class Medical Science Liasons
Best in-class Medical Science LiasonsJean-Michel Peny
 

Mais procurados (20)

CLEAR Wisdom Trial
CLEAR Wisdom TrialCLEAR Wisdom Trial
CLEAR Wisdom Trial
 
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryMedical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
 
Optimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report SummaryOptimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report Summary
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
What is a Medical Science Liaison?
What is a Medical Science Liaison?What is a Medical Science Liaison?
What is a Medical Science Liaison?
 
Medical Affairs Consortium
Medical Affairs Consortium Medical Affairs Consortium
Medical Affairs Consortium
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
 
Key Opinion Leader Management
Key Opinion Leader ManagementKey Opinion Leader Management
Key Opinion Leader Management
 
Medical Science Liaison (MSL) and KOL Regulatory Compliance
Medical Science Liaison (MSL) and KOL Regulatory ComplianceMedical Science Liaison (MSL) and KOL Regulatory Compliance
Medical Science Liaison (MSL) and KOL Regulatory Compliance
 
Strategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devicesStrategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devices
 
q2-2022-investor-presentation.pdf
q2-2022-investor-presentation.pdfq2-2022-investor-presentation.pdf
q2-2022-investor-presentation.pdf
 
Key Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
Key Opinion Leader Compensation and KOL and Medical Science Liaison InteractionsKey Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
Key Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
 
Medical Writing Canada
Medical Writing CanadaMedical Writing Canada
Medical Writing Canada
 
Early Phase Oncology Trials: A Study in Adaptation
Early Phase Oncology Trials: A Study in AdaptationEarly Phase Oncology Trials: A Study in Adaptation
Early Phase Oncology Trials: A Study in Adaptation
 
Rosuvastatin
RosuvastatinRosuvastatin
Rosuvastatin
 
KOL MANAGEMENT
KOL MANAGEMENTKOL MANAGEMENT
KOL MANAGEMENT
 
Compensation in clinical trial
Compensation in clinical trialCompensation in clinical trial
Compensation in clinical trial
 
Clinical trial design
Clinical trial designClinical trial design
Clinical trial design
 
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
 
Best in-class Medical Science Liasons
Best in-class Medical Science LiasonsBest in-class Medical Science Liasons
Best in-class Medical Science Liasons
 

Semelhante a Medical & Scientific Affairs (M & SA)

MAF Forum July 2013- Regional MAF
MAF Forum July 2013- Regional MAFMAF Forum July 2013- Regional MAF
MAF Forum July 2013- Regional MAFElena Rizova
 
E J (Ted) Shaw CV
E J (Ted) Shaw CVE J (Ted) Shaw CV
E J (Ted) Shaw CVTed Shaw
 
Marketing Techniques for Health System/Hospital-Based Retail Health Clinics
Marketing Techniques for Health System/Hospital-Based Retail Health ClinicsMarketing Techniques for Health System/Hospital-Based Retail Health Clinics
Marketing Techniques for Health System/Hospital-Based Retail Health ClinicsLegato Marketing & Communications
 
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008A.R.J. (Rob) Halkes
 
Lynn m. smith sales resume concise
Lynn m. smith sales resume conciseLynn m. smith sales resume concise
Lynn m. smith sales resume conciseLynn Smith
 
Wendy W Starr Resume
Wendy W Starr ResumeWendy W Starr Resume
Wendy W Starr ResumeWendy Starr
 
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber HelalMahmoud Bahgat
 
Towards Value Innovation In Pharma SFE Conference London 062007
Towards Value Innovation In Pharma SFE Conference London 062007Towards Value Innovation In Pharma SFE Conference London 062007
Towards Value Innovation In Pharma SFE Conference London 062007A.R.J. (Rob) Halkes
 
Radiometer 30 60 90
Radiometer 30 60 90Radiometer 30 60 90
Radiometer 30 60 90jfreshour
 
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...Best Practices, LLC
 
The physician referral pathway
The physician referral pathwayThe physician referral pathway
The physician referral pathwayCary Wing
 
Vivid Provider Mini Capabilities 2009
Vivid Provider Mini Capabilities 2009Vivid Provider Mini Capabilities 2009
Vivid Provider Mini Capabilities 2009lillianthiemann
 
2018 re con capabilitieslinkedin
2018 re con capabilitieslinkedin2018 re con capabilitieslinkedin
2018 re con capabilitieslinkedinSal Cofoni
 
Pharma "beyond the pil" - master class in St.Petersburg
Pharma "beyond the pil" - master class in St.PetersburgPharma "beyond the pil" - master class in St.Petersburg
Pharma "beyond the pil" - master class in St.PetersburgA.R.J. (Rob) Halkes
 
Senior Manager Global Medical Affairs
Senior Manager Global Medical AffairsSenior Manager Global Medical Affairs
Senior Manager Global Medical AffairsSimon Claridge
 

Semelhante a Medical & Scientific Affairs (M & SA) (20)

Regulatory Affairs
Regulatory AffairsRegulatory Affairs
Regulatory Affairs
 
Entry into the pharmaceutical and medical industry
Entry into the pharmaceutical and medical industryEntry into the pharmaceutical and medical industry
Entry into the pharmaceutical and medical industry
 
MAF Forum July 2013- Regional MAF
MAF Forum July 2013- Regional MAFMAF Forum July 2013- Regional MAF
MAF Forum July 2013- Regional MAF
 
CV New
CV NewCV New
CV New
 
E J (Ted) Shaw CV
E J (Ted) Shaw CVE J (Ted) Shaw CV
E J (Ted) Shaw CV
 
Marketing Techniques for Health System/Hospital-Based Retail Health Clinics
Marketing Techniques for Health System/Hospital-Based Retail Health ClinicsMarketing Techniques for Health System/Hospital-Based Retail Health Clinics
Marketing Techniques for Health System/Hospital-Based Retail Health Clinics
 
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
 
Lynn m. smith sales resume concise
Lynn m. smith sales resume conciseLynn m. smith sales resume concise
Lynn m. smith sales resume concise
 
Wendy W Starr Resume
Wendy W Starr ResumeWendy W Starr Resume
Wendy W Starr Resume
 
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
 
Towards Value Innovation In Pharma SFE Conference London 062007
Towards Value Innovation In Pharma SFE Conference London 062007Towards Value Innovation In Pharma SFE Conference London 062007
Towards Value Innovation In Pharma SFE Conference London 062007
 
Radiometer 30 60 90
Radiometer 30 60 90Radiometer 30 60 90
Radiometer 30 60 90
 
A shock to the system
A shock to the systemA shock to the system
A shock to the system
 
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
 
The physician referral pathway
The physician referral pathwayThe physician referral pathway
The physician referral pathway
 
Vivid Provider Mini Capabilities 2009
Vivid Provider Mini Capabilities 2009Vivid Provider Mini Capabilities 2009
Vivid Provider Mini Capabilities 2009
 
A Day in the Life of a Medical Director
A Day in the Life of a Medical DirectorA Day in the Life of a Medical Director
A Day in the Life of a Medical Director
 
2018 re con capabilitieslinkedin
2018 re con capabilitieslinkedin2018 re con capabilitieslinkedin
2018 re con capabilitieslinkedin
 
Pharma "beyond the pil" - master class in St.Petersburg
Pharma "beyond the pil" - master class in St.PetersburgPharma "beyond the pil" - master class in St.Petersburg
Pharma "beyond the pil" - master class in St.Petersburg
 
Senior Manager Global Medical Affairs
Senior Manager Global Medical AffairsSenior Manager Global Medical Affairs
Senior Manager Global Medical Affairs
 

Mais de Dr Karthik Anantharaman

Nov 2016 Medical Buyer Patient Monitors Defibrillators
Nov 2016 Medical Buyer Patient Monitors DefibrillatorsNov 2016 Medical Buyer Patient Monitors Defibrillators
Nov 2016 Medical Buyer Patient Monitors DefibrillatorsDr Karthik Anantharaman
 
Dr KA Marketing Transformation Summit 4th Aug 2016
Dr KA Marketing Transformation Summit 4th Aug 2016Dr KA Marketing Transformation Summit 4th Aug 2016
Dr KA Marketing Transformation Summit 4th Aug 2016Dr Karthik Anantharaman
 
Defibrillators Nov 2015 Medical Buyer Feature
Defibrillators Nov 2015 Medical Buyer FeatureDefibrillators Nov 2015 Medical Buyer Feature
Defibrillators Nov 2015 Medical Buyer FeatureDr Karthik Anantharaman
 
KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117Dr Karthik Anantharaman
 
ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015Dr Karthik Anantharaman
 
Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Dr Karthik Anantharaman
 
ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015Dr Karthik Anantharaman
 
Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Dr Karthik Anantharaman
 
KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117Dr Karthik Anantharaman
 
EHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
EHealth Awards Dec 2014 PPT Dr KA BPL Med TechEHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
EHealth Awards Dec 2014 PPT Dr KA BPL Med TechDr Karthik Anantharaman
 

Mais de Dr Karthik Anantharaman (20)

Nov 2016 Medical Buyer Patient Monitors Defibrillators
Nov 2016 Medical Buyer Patient Monitors DefibrillatorsNov 2016 Medical Buyer Patient Monitors Defibrillators
Nov 2016 Medical Buyer Patient Monitors Defibrillators
 
Dr KA Marketing Transformation Summit 4th Aug 2016
Dr KA Marketing Transformation Summit 4th Aug 2016Dr KA Marketing Transformation Summit 4th Aug 2016
Dr KA Marketing Transformation Summit 4th Aug 2016
 
Start Ups
Start UpsStart Ups
Start Ups
 
Defibrillators Nov 2015 Medical Buyer Feature
Defibrillators Nov 2015 Medical Buyer FeatureDefibrillators Nov 2015 Medical Buyer Feature
Defibrillators Nov 2015 Medical Buyer Feature
 
Karthik_Singapore Med Dev Asia Nov 2015
Karthik_Singapore Med Dev Asia Nov 2015Karthik_Singapore Med Dev Asia Nov 2015
Karthik_Singapore Med Dev Asia Nov 2015
 
Karthik_Shanghai
Karthik_ShanghaiKarthik_Shanghai
Karthik_Shanghai
 
KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117
 
eHealth Connected Healthcare July 2015
eHealth Connected Healthcare July 2015eHealth Connected Healthcare July 2015
eHealth Connected Healthcare July 2015
 
ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015
 
Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014
 
ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015
 
Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014
 
eHealth Connected Healthcare July 2015
eHealth Connected Healthcare July 2015eHealth Connected Healthcare July 2015
eHealth Connected Healthcare July 2015
 
KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117
 
Lifephone B2B
Lifephone B2BLifephone B2B
Lifephone B2B
 
EHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
EHealth Awards Dec 2014 PPT Dr KA BPL Med TechEHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
EHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
 
Comparison Of The Major Carbapenems
Comparison Of The Major CarbapenemsComparison Of The Major Carbapenems
Comparison Of The Major Carbapenems
 
Dr KA Apicon Master Slide Presentation
Dr KA Apicon Master Slide PresentationDr KA Apicon Master Slide Presentation
Dr KA Apicon Master Slide Presentation
 
Msd Trivandrum Dr Ka
Msd Trivandrum Dr KaMsd Trivandrum Dr Ka
Msd Trivandrum Dr Ka
 
Msd Orissa Apicon Nov 2008 Dr Ka
Msd Orissa Apicon Nov 2008 Dr KaMsd Orissa Apicon Nov 2008 Dr Ka
Msd Orissa Apicon Nov 2008 Dr Ka
 

Medical & Scientific Affairs (M & SA)

  • 1. Medical & Scientific Affairs (M & SA) A critical piece in the puzzle of building organizational equity Dr Karthik Anantharaman Head of Medical Team Integrated Disease Management Pvt Ltd
  • 2.
  • 3.
  • 4. Roles & Responsibilities of M & SA understood to be in-line with Differentiated Strategic Intent of organization Customer Few Disease Management Many Product Therapeutic Areas Offering Doctor Patients IDM Scientific rigour for patented ‘first in class’ brands Establish both ‘Science’ & ‘Story’ of the brand Health Outcome Partner to physicians to improve patient outcomes Establish brand as a ‘SOLUTION’ & not a tablet Most Large Pharma Companies in India “ Differentiated” Intent
  • 5. M & SA responsibility: The fine balance Scientific & Research based communication – Non product related, Focus on Disease Management, Guideline Compliance (fair, balanced, non-promotional, build organizational equity thru scientific excellence) Science based product related discussions / objection handling / query management
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. Responsibilities of M & SA Sales Marketing RTM KAM M & SA Medical / MRL / Regulatory Corporate Business (1) Direct Business Development Priorities (Conventional)
  • 11. Responsibilities of M & SA Sales PV IDM Office of Compliance M & SA Medical / MRL / Regulatory External Partnerships CSR (2) Incremental Business Development Priorities PCP / Patient Support Programs
  • 12. Completing the picture: All Responsibilities of M & SA Sales Marketing RTM KAM PV IDM Office of Compliance M & SA Medical / MRL / Regulatory External Partnerships Corporate Business CSR CSA / Patient Support Counselors
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19. Role of Team M & SA in Business Strategy Strategy building team BUD + Marketing + NBM Head – M & SA Output = BU Strategy Strategy roll-out team Medical Advisor Marketing Manager M & SA Manager M & SA Implementation Pre-implementation (if any) (blue) & Post-implementation (green) M & SA Inputs / feedback Into BU Strategy (Attachment 1)
  • 20. M & SA : Feedback & Performance Management Customers of M & SA Internal customers (Sales & Marketing) External customers (Doctors) *RBM feedback on respective M & SA(monthly) (Attachment 4) **Training feedback (Attachment 5) M & SA Mgr Consolidated monthly feedback to individual M & SA Individual Coaching & Counseling Supervisor Doctor feedback (consolidated monthly): **CME quality feedback (Attachment 6) **Medical Query quality feedback (Attachment 7) M & SA Manager Monthly Field trip report (Attachment 8) Assessment of Business Enabling Capabilities Assessment of Technical & Management capabilities Assessment of Technical capabilities *Reported on last working day of the month **incorporated in monthly report
  • 21. PPG/KRA Alignment of Team M & SA Head M & SA Regional M & SA Mgr Regional M & SA Mgr M & SA M & SA Regional M & SA Mgr M & SA Medical Director S & M Director (consolidated for all BUs) BU specific (Aligned to BUD’s PPG) BU specific (Aligned to BUD’s PPG) BU specific (Aligned to BUD’s PPG)
  • 22. Resource Planning - Methodology Variables Weightage CoP Network (Region-wise) (Focus segment for KOL Management) 50% Field Deployment 50% Number of medico-marketing activities based on BU strategy
  • 23.  
  • 25.

Notas do Editor

  1. Most companies have the following strategy: Operate in a large number of Disease Areas Focus on expanding product distribution Restrict their customer contact primarily to the doctor We propose a differentiated strategy Focus on key disease areas with high potential Engage with the patient directly while partnering with the doctor Going beyond product availability to providing an augmented product which includes services for disease management